Get started
Author

Sherri Cicero

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
2013 · Andre Goy, Rajni Sinha, et al. · Journal of Clinical Oncology · 349
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
2015 · Andre Goy, Sevgi Kalayoglu Besisik, et al. · British Journal of Haematology · 41
PDF
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study
2012 · Andre Goy, Rajni Sinha, et al. · Blood · 17
Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study.
2013 · Michael E. Williams, Andre Goy, et al. · Journal of Clinical Oncology · 4
Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
2013 · Thomas E. Witzig, Julie Vose, et al. · Journal of Clinical Oncology · 3
Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib
2013 · Andre Goy, Michael E. Williams, et al. · Blood · 2
Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 “EMERGE” Study
2014 · Andre Goy, Michael E. Williams, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
P3‐018: An Evaluation of the Safety of Nelotanserin, A Highly Potent and Selective 5‐HT2A Inverse Agonist That is Being Developed as a Treatment for Visual Hallucinations and REM Behavior Disorder in Lewy Body Dementia
2016 · Warren Wen, Shankar Ramaswamy, et al. · Alzheimer s & Dementia
Works count: 8
Citation count: 417
H-index: 4
I10-index: 3
Year
Topic
Type